Colorectal cancer has long baffled scientists because, unlike most tumors, patients often do better when their cancers are ...

Quell Therapeutics is pressing pause on an engineered regulatory T (Treg) cell therapy for liver transplant patients in order to focus resources on a preclinical autoimmune candidate. | Quell ...

Regeneron Pharmaceuticals already has a presence in immunology, but nothing in its portfolio or pipeline addresses inflammatory bowel disorders nor does the drugmaker have any cell therapies. The ...

A small study suggests Mavenclad’s effectiveness in MS may be linked to how regulatory T-cells respond to treatment.

London, UK – 25 October, 2025 – Quell Therapeutics Ltd (“Quell”), a pioneer in engineered T-regulatory (Treg) cell therapies for people with immune-mediated diseases, will present promising data from ...

A special group of immune cells known as regulatory T cells, or Tregs for short, became an overnight sensation when a trio of U.S. and Japanese scientists won the Nobel Prize in physiology or medicine ...

TRexBio Closes $50 Million Financing to Support a Growing Clinical-Stage Immunology Pipeline of Tissue-Targeted Treg Therapeutics ...

Sonoma Biotherapeutics launched with a mission to create regulatory T-cell treatments for autoimmune and neurodegenerative diseases, $40 million in series A financing and renowned immunologist, ...

Understanding how regulatory T cells (Tregs) develop and work is key to determining how they might be manipulated to encourage the destruction of cancer cells or prevent autoimmunity. Cell behavior is ...

Prakash Nagarkatti receives funding from the National Institutes of Health. Mitzi Nagarkatti receives funding from the National Institutes of Health. A special group of immune cells known as ...